12-25245349-ACC-GCT

Variant summary

Our verdict is Likely pathogenic.
+9 Likely Pathogenic
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received 9 classification points (ACGS-UK Somatic Oncogenicity v2025). O3_ModerateO5_ModerateO7_StrongO8_Supporting

The NM_004985.5(KRAS):c.34_36delGGTinsAGC (p.Gly12Ser) variant causes a missense change. The gene KRAS is a known oncogene (CancerMine: 2 TSG, 2158 oncogene, 346 driver citations). The gene KRAS is a cancer driver gene (CancerMine: 2 TSG, 2158 oncogene, 346 driver citations). Note: allele frequency estimates from gnomAD may be inaccurate for this variant type (MNP or indel longer than 3 bp) due to technology limitations. The variant is absent from the gnomAD population database at sites with sufficient sequencing coverage. The affected nucleotide is highly conserved across species (PhyloP 100-way vertebrate score: 7.89). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar. A different missense at the same amino acid position has been reported as Pathogenic/Likely Pathogenic in ClinVar: p.G12C: Likely_pathogenic (ClinVar VariationId 12578, 1 star) Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.G12= (synonymous): Likely_benign (ClinVar VariationId 1734094, 1 star); p.G12= (synonymous): Likely_benign (ClinVar VariationId 4859020, 1 star); p.G12= (synonymous): Likely_benign (ClinVar VariationId 1734090, 1 star) The same amino acid change has been reported as oncogenic or likely oncogenic in a clinical somatic variant database. The variant position is a cancer hotspot (cancerhotspots.org): 2910 samples carry this exact amino acid change out of 32010 samples with a variant at this residue. This exact variant is curated in the UniProt human variants database as Pathogenic, associated with Juvenile myelomonocytic leukemia (jmml); it is also listed as a COSMIC curated somatic variant.

Frequency

Genomes: not found (cov: 32)

Consequence

KRAS
NM_004985.5 missense

Scores

Not classified

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: 7.89

Publications

0 publications found
Variant links:
Genes affected
KRAS (HGNC:6407): (KRas proto-oncogene, GTPase) This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]
KRAS Gene-Disease associations (from GenCC):
  • cardiofaciocutaneous syndrome 2
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), PanelApp Australia, Ambry Genetics, G2P
  • Noonan syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
  • Noonan syndrome 3
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, PanelApp Australia, Labcorp Genetics (formerly Invitae), Ambry Genetics, Genomics England PanelApp
  • autoimmune lymphoproliferative syndrome type 4
    Inheritance: AD Classification: STRONG Submitted by: PanelApp Australia
  • cardiofaciocutaneous syndrome
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, ClinGen
  • linear nevus sebaceous syndrome
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • Costello syndrome
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_004985.5, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACGS-UK Somatic Oncogenicity v2025

Classification was made for transcript:

Our verdict: Likely_pathogenic. The variant received 9 points.

O3Absent or very rare in population
Absent or extremely rare in gnomAD (AC ≤ 2) — O3 moderate; GnomAD: AF = absent, AC = 0 — absent/extremely rare (O3 moderate [+2])
O5Same location/impact as known oncogenic
Same AA change as established oncogenic variant (or germline P/LP in TSG) — Moderate (O5); ClinVar same-AA oncogenic/T1: true | ClinVar same-AA SCI tier: — | CGI same-AA oncogenic: true | TSG: false | ClinVar same-AA germline P/LP: true | CIViC LOF: false | ClinVar diff-AA oncogenic: true | ClinVar diff-AA germline P/LP: true
O7Mutational hotspot or critical domain
Strong hotspot (cancerhotspots.org): >50 total samples, ≥10 same AA change; Note: exclude MSK/TCGA-derived samples from cancerhotspots count to avoid double-counting with O4; cancerhotspots.org: total samples at AA position = 32010, same AA change = 2910; Exclude MSK/TCGA-derived samples from count to avoid double-counting with O4; UniProt domain: 0 pathogenic, 0 benign.; ±8 AA neighbourhood: 16 pathogenic, 0 benign (OR vs. background: 165.0); Variant does not impact splicing — splice-hotspot path not applicable
O8Missense constraint in gene or region
Missense in gene/domain constrained for missense variation where missense is common disease mechanism (O8 supporting); Gene/disease mechanism: missense is a common mechanism of oncogenesis; gnomAD missense Z-score: 3.09 (threshold ≥3.09 for constraint); Domain-level constraint: variant is in a critically constrained functional domain (IS_AT_CRITICAL_DOMAIN)

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_004985.5. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

KRAS NM_033360.4
MANE Plus Clinical
HGVSc / HGVSpc.34_36delGGTinsAGCp.Gly12Ser
Exon rankN/A
missense
Prot: NP_203524.1UniProt: P01116-1
KRAS NM_004985.5
MANE Select
HGVSc / HGVSpc.34_36delGGTinsAGCp.Gly12Ser
Exon rankN/A
missense
Prot: NP_004976.2
KRAS NM_001369786.1
HGVSc / HGVSpc.34_36delGGTinsAGCp.Gly12Ser
Exon rankN/A
missense
Prot: NP_001356715.1UniProt: P01116-1

Ensembl Transcripts

KRAS ENST00000256078.10
TSL:1MANE Plus Clinical
HGVSc / HGVSpc.34_36delGGTinsAGCp.Gly12Ser
Exon rankN/A
missense
Prot: ENSP00000256078.5UniProt: P01116-1
KRAS ENST00000311936.8
TSL:1MANE Select
HGVSc / HGVSpc.34_36delGGTinsAGCp.Gly12Ser
Exon rankN/A
missense
Prot: ENSP00000308495.3UniProt: P01116-2
KRAS ENST00000556131.2
TSL:1
HGVSc / HGVSpc.34_36delGGTinsAGCp.Gly12Ser
Exon rankN/A
missense
Prot: ENSP00000451856.1UniProt: G3V4K2

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)
Rare (AF ≤ 0.0001 / Hom ≤ 1)
Global population databases 2 sources
GnomAD3 genomes
Cov:32
GnomAD4 genome
Cov:32
Showing 2 sources
Tested, but no data found:GnomAD4 exomeIf GnomAD4 is missing, the position is probably not covered by the project.

ClinVar

Not reported in ClinVar

Computational Scores

PhyloP100
Pathogenic7.9
Showing 1 of 1 scores

Splicing Scores

No splicing scores have been computed for this variant.

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

14 no calibration
Protein level
binding fitness from KRAS-SOS1 bindingPCA of KRAS block1
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
-0.175 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 85th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
abundance fitness from abundancePCA of KRAS block1
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
-0.163 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 76th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding fitness from KRAS-PIK3CGRDB bindingPCA of KRAS block1
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
-0.0238 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 87th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding fitness from KRAS-RALGDSRDB bindingPCA of KRAS block1
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
-0.00935 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 93th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding fitness from KRAS-RAF1RDB bindingPCA of KRAS block1
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
-0.0723 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 89th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding free energy changes of KRAS-SOS1 interaction
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
0.126 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 50th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding free energy changes of KRAS-RAF1RBD interaction
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
0.0234 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 47th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
folding free energy changes of KRAS in abundancePCA
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
0.395 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 54th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding fitness from KRAS-DARPin K27 bindingPCA of KRAS block1
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
-0.283 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 71th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding free energy changes of KRAS-RALGDSRBD interaction
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
-0.174 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 17th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding fitness from KRAS-DARPin K55 bindingPCA of KRAS block1
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
-0.0312 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 93th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding free energy changes of KRAS-DARPin K27 interaction
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
0.283 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 78th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding free energy changes of KRAS-PIK3CGRBD interaction
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
-0.116 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 20th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.
Protein level
binding free energy changes of KRAS-DARPin K55 interaction
The energetic and allosteric landscape for KRAS inhibition
Gene
KRAS
Score
-0.104 · p.Gly12Ser (assay numbering)
No calibration data
This score is at approximately the 30th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.

Publications

Other links and lift over

For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.